Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Short communication

The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers

Authors: Iwona Ziółkowska-Suchanek, Maria Mosor, Małgorzata Wierzbicka, Małgorzata Rydzanicz, Marta Baranowska, Jerzy Nowak

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

The members of MRE11/RAD50/NBN (MRN) protein complex participates in DNA double-strand break repair and DNA-damage checkpoint activation. We have previously shown that the p.I171V NBN gene mutation may contribute to the development of laryngeal cancer. This study tested the hypothesis that variants of the MRE11 and RAD50 genes, previously described as cancer risk factors, predispose to increased susceptibility to head and neck cancer.

Findings

In this study we analyzed the RAD50 and MRE11 genes in 358 patients: 175 with a single laryngeal cancer (LC), 115 with multiple primary tumors but one malignancy (primary or second) localized in the larynx (MPT-LC), 68 patients with multiple primary tumors localized in the head or neck (MPT) and 506 controls. No carriers of previously reported mutation in the MRE11 or RAD50 gene (particularly the pathogenic c.687delT) were detected in the present study. We identified the p.V127I variant (2/175 LC, 2/506 controls; OR=2.91; 95% CI 0.41-20.85) and p.V315L variant (2/115 MPT-LC, 1/506 controls; OR=8.96; 95% CI 0.81-99.68) of the RAD50 gene.

Conclusions

Our data indicated that previously described common genetic variations in the MRE11 and RAD50 genes do not contribute to an increased risk of laryngeal cancer and second primary tumors localized in the head and neck. Prospective studies with larger groups of patients may reveal the possible impact of these genes in tumor occurrence.
Literature
1.
Cianfriglia F, Di Gregorio DA, Manieri A: Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol. 1999, 35: 157-163.CrossRefPubMed
2.
Warren S, Gates O: Multiple primary malignant tumors: survey of the literature and statistical study. Am J Cancer. 1932, 16: 1358-
3.
Williams GJ, Lees-Miller SP, Tainer JA: Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst). 2010, 9: 1299-1306. 10.1016/j.dnarep.2010.10.001.CrossRef
4.
Mosor M, Ziółkowska I, Pernak-Schwarz M, Januszkiewicz-Lewandowska D, Nowak J: Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia. Leukemia. 2006, 20: 1454-1456.CrossRefPubMed
5.
Dzikiewicz-Krawczyk A: The importance of making ends meet: mutations in genes and altered expression of proteins of the MRN complex and cancer. Mutat Res. 2008, 659: 262-273.CrossRefPubMed
6.
Heikkinen K, Karppinen SM, Soini Y, Makinen M, Winqvist R: Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J of med genet. 2003, 40: 131-10.1136/jmg.40.12.e131.CrossRef
7.
Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundán T, Mannermaa A, Børresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R: RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006, 27: 1593-1599.PubMedCentralCrossRefPubMed
8.
Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J: Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008, 2: 296-316.CrossRefPubMed
9.
Ziółkowska I, Mosor M, Wierzbicka M, Rydzanicz M, Pernak-Schwarz M, Nowak J: Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene. Cancer Sci. 2007, 98: 1701-1705.CrossRefPubMed
10.
Ziółkowska-Suchanek I, Mosor M, Wierzbicka M, Fichna M, Rydzanicz M, Nowak J: Association of polymorphisms and haplotypes of the NBN gene with laryngeal cancer and multiple primary tumors of the head and neck. Head Neck. 2012, 34: 376-383.CrossRefPubMed
11.
Mosor M, Ziółkowska-Suchanek I, Roznowski K, Baranowska M, Januszkiewicz-Lewandowska D, Nowak J: RAD50 gene mutations are not likely a risk factor for breast cancer in Poland. Breast Cancer Res Treat. 2010, 123: 607-609.CrossRefPubMed
12.
Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995, 57: 289-300.
13.
Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkilä P, Evans DG, Eccles D, Aittomäki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N: Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer. 2006, 118: 2911-2916.CrossRefPubMed
14.
Uhrhammer N, Delort L, Bignon YJ: Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol Biomarkers Prev. 2009, 18: 684-685.CrossRefPubMed
15.
Schuetz JM, MaCarthur AC, Leach S, Lai AS, Gallagher RP, Connors JM, Gascoyne RD, Spinelli JJ, Brooks-Wilson AR: Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. BMC Med Genet. 2009, 16: 117-CrossRef
16.
Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC: Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev. 2007, 16: 2024-2032.CrossRefPubMed
17.
Choudhury A, Elliott F, Iles MM, Churchman M, Bristow RG, Bishop DT, Kiltie AE: Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet. 2008, 9: 69-PubMedCentralCrossRefPubMed
18.
Mosor M, Ziółkowska-Suchanek I, Nowicka K, Dzikiewicz-Krawczyk A, Januszkiewicz–Lewandowska D, Nowak J: Germline mutations in MRE11/RAD50/NBN complex genes in childhood leukemia. BMC Cancer. 2013, in press
Metadata
Title
The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers
Authors
Iwona Ziółkowska-Suchanek
Maria Mosor
Małgorzata Wierzbicka
Małgorzata Rydzanicz
Marta Baranowska
Jerzy Nowak
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-113

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer

Research

A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation

Research

MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma

Research

The long non-coding RNA ERIC is regulated by E2F and modulates the cellular response to DNA damage

Research

The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma

Research

Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits